Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease: Infliximab may normalize activation patterns

Csaba Orbán, Dolóresz Szabó, Anna Bajnok, B. Vásárhelyi, T. Tulassay, A. Arató, G. Veres, Gergely Toldi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Crohn's disease is a chronic inflammation of the gastrointestinal tract with an abnormal immune phenotype. We investigated how intracellular calcium kinetics of Th1 and Th2 lymphocytes alter upon specific inhibition of Kv1.3 and IKCa1 channels in pediatric Crohn's disease. Study design: Blood was taken from 12 healthy and 29 Crohn's disease children. Of those, 6 were switched to infliximab and re-sampled after the 4th infliximab treatment. Intracellular calcium levels were monitored using flow cytometry in the presence or absence of specific inhibitors of Kv1.3 and IKCa1 potassium channels. Results: In Crohn's disease treated with standard therapy, calcium response during activation was higher than normal in Th2 cells. This was normalized in vitro by inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab, potassium channel function and expression in Th2 lymphocytes were comparable to those in Th1 cells. Conclusion: These results may indicate that potassium channels are potential immune modulatory targets in Crohn's disease.

Original languageEnglish
Pages (from-to)44966-44974
Number of pages9
JournalOncotarget
Volume7
Issue number29
DOIs
Publication statusPublished - 2016

Fingerprint

Th2 Cells
Crohn Disease
Potassium Channels
Calcium
Kv1.3 Potassium Channel
Lymphocytes
Th1 Cells
Gastrointestinal Tract
Flow Cytometry
Inflammation
Phenotype
Infliximab
Pediatric Crohn's disease
Therapeutics

Keywords

  • Crohn's disease
  • IKCa1
  • Immune response
  • Immunity
  • Immunology and Microbiology Section
  • Infliximab
  • Kv1.3
  • Th2

ASJC Scopus subject areas

  • Oncology

Cite this

Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease : Infliximab may normalize activation patterns. / Orbán, Csaba; Szabó, Dolóresz; Bajnok, Anna; Vásárhelyi, B.; Tulassay, T.; Arató, A.; Veres, G.; Toldi, Gergely.

In: Oncotarget, Vol. 7, No. 29, 2016, p. 44966-44974.

Research output: Contribution to journalArticle

@article{1ffb26805f264ecfa2d984cfe3870a60,
title = "Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease: Infliximab may normalize activation patterns",
abstract = "Objective: Crohn's disease is a chronic inflammation of the gastrointestinal tract with an abnormal immune phenotype. We investigated how intracellular calcium kinetics of Th1 and Th2 lymphocytes alter upon specific inhibition of Kv1.3 and IKCa1 channels in pediatric Crohn's disease. Study design: Blood was taken from 12 healthy and 29 Crohn's disease children. Of those, 6 were switched to infliximab and re-sampled after the 4th infliximab treatment. Intracellular calcium levels were monitored using flow cytometry in the presence or absence of specific inhibitors of Kv1.3 and IKCa1 potassium channels. Results: In Crohn's disease treated with standard therapy, calcium response during activation was higher than normal in Th2 cells. This was normalized in vitro by inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab, potassium channel function and expression in Th2 lymphocytes were comparable to those in Th1 cells. Conclusion: These results may indicate that potassium channels are potential immune modulatory targets in Crohn's disease.",
keywords = "Crohn's disease, IKCa1, Immune response, Immunity, Immunology and Microbiology Section, Infliximab, Kv1.3, Th2",
author = "Csaba Orb{\'a}n and Dol{\'o}resz Szab{\'o} and Anna Bajnok and B. V{\'a}s{\'a}rhelyi and T. Tulassay and A. Arat{\'o} and G. Veres and Gergely Toldi",
year = "2016",
doi = "10.18632/oncotarget.10036",
language = "English",
volume = "7",
pages = "44966--44974",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

TY - JOUR

T1 - Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease

T2 - Infliximab may normalize activation patterns

AU - Orbán, Csaba

AU - Szabó, Dolóresz

AU - Bajnok, Anna

AU - Vásárhelyi, B.

AU - Tulassay, T.

AU - Arató, A.

AU - Veres, G.

AU - Toldi, Gergely

PY - 2016

Y1 - 2016

N2 - Objective: Crohn's disease is a chronic inflammation of the gastrointestinal tract with an abnormal immune phenotype. We investigated how intracellular calcium kinetics of Th1 and Th2 lymphocytes alter upon specific inhibition of Kv1.3 and IKCa1 channels in pediatric Crohn's disease. Study design: Blood was taken from 12 healthy and 29 Crohn's disease children. Of those, 6 were switched to infliximab and re-sampled after the 4th infliximab treatment. Intracellular calcium levels were monitored using flow cytometry in the presence or absence of specific inhibitors of Kv1.3 and IKCa1 potassium channels. Results: In Crohn's disease treated with standard therapy, calcium response during activation was higher than normal in Th2 cells. This was normalized in vitro by inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab, potassium channel function and expression in Th2 lymphocytes were comparable to those in Th1 cells. Conclusion: These results may indicate that potassium channels are potential immune modulatory targets in Crohn's disease.

AB - Objective: Crohn's disease is a chronic inflammation of the gastrointestinal tract with an abnormal immune phenotype. We investigated how intracellular calcium kinetics of Th1 and Th2 lymphocytes alter upon specific inhibition of Kv1.3 and IKCa1 channels in pediatric Crohn's disease. Study design: Blood was taken from 12 healthy and 29 Crohn's disease children. Of those, 6 were switched to infliximab and re-sampled after the 4th infliximab treatment. Intracellular calcium levels were monitored using flow cytometry in the presence or absence of specific inhibitors of Kv1.3 and IKCa1 potassium channels. Results: In Crohn's disease treated with standard therapy, calcium response during activation was higher than normal in Th2 cells. This was normalized in vitro by inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab, potassium channel function and expression in Th2 lymphocytes were comparable to those in Th1 cells. Conclusion: These results may indicate that potassium channels are potential immune modulatory targets in Crohn's disease.

KW - Crohn's disease

KW - IKCa1

KW - Immune response

KW - Immunity

KW - Immunology and Microbiology Section

KW - Infliximab

KW - Kv1.3

KW - Th2

UR - http://www.scopus.com/inward/record.url?scp=84979892926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979892926&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10036

DO - 10.18632/oncotarget.10036

M3 - Article

C2 - 27329601

AN - SCOPUS:84979892926

VL - 7

SP - 44966

EP - 44974

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -